The ExoDx™ Prostate Test
Introducing the only exosome-based prostate cancer test delivering a unique data point to help guide the prostate biopsy decision. The ExoDx Prostate test is included in the NCCN Guidelines, and is independent of PSA and other standard of care (SOC) information.
For TeleMedicine visits, check out the At-Home Collection Kit!
Assess prostate cancer risk
Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer
Precisely predictive, clinically convenient
Simple urine test, non-DRE, included in the NCCN guidelines to help guide your patient to biopsy decision
A new standard in prostate risk assessment
Clinical studies demonstrate the ExoDx Prostate test discriminates between high-grade and low-grade prostate cancer and benign disease
A treasure trove of RNA, DNA and protein
Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs
ExoDx™ Prostate Test For U.S. Veterans
The ExoDxTM Prostate test is now available to U.S. Veterans. The Veteran population has a two-fold increased risk of prostate cancer incidence compared to the general population but if detected early, prostate cancer is treatable. The ExoDx™ Prostate Test (EPI) provides actionable information that aids the prostate biopsy decision for men with PSA in the ‘gray zone’ of 2–10 ng/mL and is not dependent on other clinical risk factors. Learn more about the EPI test including a testimonial of how the ExoDx Prostate test helped a 61-year old man facing a prostate biopsy.
What's New
-
Industry Workshop Exosome Diagnostics - New Innovations: Use of a liquid biomarker as a risk assessment tool for use in early detection of prostate cancer
-
Smarter Screening for Prostate Cancer: The Road Forward in 2021 with Dr. Matthew Cooperberg
-
Prostate Cancer Risk Assessment: Getting Beyond PSA With Dr. Sanoj Punnen
-
-
Entering the Chat Room of Cancer Cells - How They Talk and Why We Should Listen
-
How the ExoDx Prostate Test Impacts Urology Practice in a Real-World Clinical Setting
-
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study
-
-
ExoDx Prostate Test: Implications for Value-Based Care with Dr. Judd Moul
-
Medicare Issues Final Local Coverage Decision for Bio-Techne's ExoDx Prostate (Intelliscore) Test
-
ExoDx Prostate(IntelliScore) (EPI) Included in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Stay in Touch with ExosomeDx
Join our Mailing LIstReceive updates and scientific advances
Meet the ExosomeDx Team
The ExoDx Prostate test is a simple urine test that detects three important genomic biomarkers that are markers of high-grade prostate cancer. Using this assessment, the physician can determine whether or not a patient should undergo a diagnostic biopsy.
Gaining access to molecular information from biofluids without needing direct access to the tissue itself will have far-reaching implications in patient management. While our diagnostics are initially focused on cancer, our exosome-based technology platform is potentially applicable to other diseases or medical conditions where molecular testing is beneficial, but where access to tissue is difficult or impossible.
"To us, it's all about the patients and helping them through the process. This changes everything" - Dr. Johan Skog, Chief Scientific Officer:
Partner with Exosome Diagnostics
Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".
Dr. Johan Skog is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael Valentino is Exosome Diagnostic's Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.
